Celiac Disease Market Growth, Size, Share, Industry Report and Forecast 2021-2027

The global celiac disease market is anticipated to grow significantly at a CAGR of 8.5% during the forecast period. Celiac disease is a digestive disorder in which the body has trouble absorbing nutrients such as lipids, calcium, iron, and folate. It is an autoimmune illness induced by eating gluten, which damages the small intestine's inner lining. Several diseases and conditions, including neurological abnormalities, infertility, reduced bone density, and some cancers, can be caused by the disease. People with type 1 diabetes, down syndrome, autoimmune thyroid disease, microscopic colitis, Addison's disease, and rheumatoid arthritis are at risk for this hereditary condition. Besides, the market for celiac disease therapy is predicted to rise significantly in the forecast period, owing to the development of several anti-inflammatory medications and therapeutic vaccinations that will replace or enhance a gluten-free diet.

To Request a Sample of our Report on Celiac Disease Market: https://www.omrglobal.com/request-sample/celiac-disease-market

The organization of various awareness programs and initiatives taken by the government in various nations for the treatment of celiac disease is a major factor that is driving the growth of the global celiac disease market. With such actions, the government may significantly stimulate market growth. Furthermore, numerous funds are available for R&D operations, which is propelling market expansion. For instance, in 2015, in Italy, children and adults with certain symptoms are tested for celiac disease. Diagnosed celiacs are given vouchers worth up to $168 per month to spend on specially made gluten-free meals. Furthermore, restaurants are educated on how to deal with celiac disease by the Italian Celiac Association and the government. Gluten-free meals are even available at hospitals, schools, and other public eating facilities.

(Get 15% Discount on Buying this Report)

A full Report of Celiac Disease Market is Available at: https://www.omrglobal.com/industry-reports/celiac-disease-market

Global Celiac Disease Market Segmentation

By Treatment Type

· Vitamins and Dietary (Gluten-Free) Supplements

· Steroids and Immunosuppressive Drugs

· Therapeutic Vaccines

By Diagnostic Type

· Serologic Test

· Genetic Testing

· Small-Bowel Biopsy

By End-User

· Hospitals and Diagnostics Centers

· Research Institutes

Regional Analysis

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

Company Profiles

· Abbott Laboratories

· AbbVie Inc.

· ADMA Biologics, Inc.

· Amgen Inc.

· Bayer AG

· Bio Rad Laboratories, Inc.

· BioLineRX Ltd.

· Boston Scientific Corp.

· Bristol-Myers Squibb Co.

· Calypso Biotech SA

· ChemoCentryx, Inc.

· Eli Lilly And Co.

· GlaxoSmithKline plc

· ImmunogenX, Inc.

· Janssen Pharmaceuticals, Inc.

· Johnson & Johnson Services Inc.,

· Merck & Co., Inc.,

· Sanofi S.A

· Thermo Fisher Scientific Inc.

· ZEDIRA GmbH

Reasons to buy from us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/celiac-disease-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.